US FDA Gets Earful On Biologic ‘Umbrella’ Exclusivity, Patent Listings, Biosimilar Bridging Study Waivers

 
• By Sue Sutter
  
Man with hearing problem on grey background, closeup
US FDA heard plenty of feedback from industry trade groups on issues involving biosimilar competition and product innovation.
Pink Sheet Podcast

Have you checked out Pink Sheet podcast?

New episodes every Thursday.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics